To include your compound in the COVID-19 Resource Center, submit it here.

Foresee reports Phase I data for asthma/COPD candidate

Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) reported data from a pair of double-blind Phase I trials

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE